alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topic

Plasma and spinal-fluid biomarkers

1,573 studies in this group. A computer grouped them by what their titles and summaries are about, not by a hand-made list. The name describes most of the group, not every study in it.

Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.

Highest usefulness score first. Studies without a score come last.

  1. Neurovascular Outer Retinal Degeneration in Presymptomatic Alzheimer’s Disease: An Oculomic Biomarker Study

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-07-15 Biomarkers

    These findings demonstrate spatially concordant vascular and neuronal degeneration in the outer retina in preclinical AD.

  2. Biomarker Variability Limits Individualized Amyloid Time Estimation in Alzheimer Disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-07-13 Brain scans and imaging

    DPM is fundamentally constrained by dynamic range, variability, and test–retest reliability of the biomarker of interest.

  3. MCH-Guard: Multimodal Machine Learning Framework for Risk Stratification of Cerebral Microhemorrhage Risk in the Alzheimer’s Disease Neuroimaging Initiative

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-06-22 Treatments

    MCH-Guard offers a flexible clinical decision-support tool for optimizing spontaneous MCH & ARIA surveillance.

  4. Dynamic Imaging Markers of ARIA-H Risk in the A4 Study: A Person-Interval Analysis of Current Lesion Burden and Recent Microhaemorrhage Activity

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-06-02 Treatments

    Temporal imaging variables may provide independent prognostic information beyond baseline risk, supporting a dynamic model of haemorrhagic risk in Alzheimer’s disease.

  5. Automated quantification of cerebral microbleeds for ARIA-H monitoring in Aging and Alzheimer’s Disease: A multicenter deep learning validation

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-05-26 Treatments

    We trained a self-configuring nnU-Net model for CMB segmentation in a hetero-geneous multicenter sample ( n =264), including 1.5T and 3T field strengths, SWI and T2*-GRE sequences, and community and clinical cohorts.

  6. CNS-selective plasma p-tau217 accurately captures Alzheimer's disease pathology and progression

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv : the preprint server for health sciences 2026-05-21 Biomarkers

    Blood-based biomarkers have expanded access to biologically supported diagnosis of Alzheimer's disease (AD), particularly through measurement of amyloid-beta (Aβ) and phosphorylated tau species1-3.

  7. Real-World Performance of Urine β-amyloid Test Kits in Multiple Hospital Clinics and Neighborhood Communities of China

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-05-15 Treatments

    Our findings confirm the diagnostic value of urinary β-amyloid protein detection in MCI and AD-related dementia.

  8. Predicting the age of Alzheimer’s symptom onset from a blood test: evaluating a prognostic claim

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-04-01 Biomarkers

    The clock claims are unsupported.

  9. Association of infections and autoimmune conditions with cognition: a study using self-reported conditions and identifying a novel plasma biomarker

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-02-17 Biomarkers

    a Structured abstract BACKGROUND Over the past couple of decades, the role of infections, as well as the involvement of the immune system, have been highlighted in the development of dementia.

  10. Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health System

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-01-25 Treatments

    The overall incidence of any ARIA was 25.2%, with ARIA-H occurring in 22.4% of patients and ARIA-E in 12.2%.

  11. Measurement of tau protein and Aβ amyloid plaques in postmortem human brains of Down syndrome and Alzheimer’s disease by using [ 125 I]IPPI and [ 125 I]IBETA autoradiography

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. bioRxiv 2026-01-21 Drug development

    The accumulation of tau tangles and Aβ plaques are prominent neuropathologies that characterize Alzheimer’s disease (AD) and Down Syndrome (DS).

  12. Effect of prior traumatic brain injury on Alzheimer’s disease blood biomarkers in Vietnam Veterans

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2026-01-15 Biomarkers

    In this cross-sectional study (n=272), plasma pTau217/Aβ42 ratio test accuracy was 90% in Veterans without TBI history, but was significantly lower (63-78% accuracy) in Veterans with TBI history, with lowest accuracy in those with greater TBI severity.

  13. Genetic architecture of Alzheimer’s disease-related plasma biomarkers

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-12-18 Biomarkers

    The observed phenotypic and genetic associations highlight shared underlying mechanisms among plasma biomarkers.

  14. MRI measures of cortical microstructural damage associate with tau accumulation in presymptomatic Alzheimer’s disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-12-16 Treatments

    NODDI-derived ODI is associated with tau PET signal, even in preclinical disease and may discriminate individuals with-and without tau beyond the MTL.

  15. Investigating the Amyloid-Tau-Neurodegeneration Framework in Alzheimer’s Disease Using Semi-Supervised Multimodal Imaging Data Fusion

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv 2025-12-15 Brain scans and imaging

    Semi-supervised multimodal fusion improves prediction and reveals interpretable imaging patterns that predict APOE4 and clinical diagnoses better than traditional approaches.

  16. Plasma pTau-181 Exhibits Flat Longitudinal Trajectories and Weak Cognitive Correlation in UK Biobank: Implications for Anti-Tau Antibody Trial Failures

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2025-12-01 Drug development

    Plasma pTau-181 demonstrates flat or declining longitudinal trajectories and minimal cognitive correlation, suggesting tau is a static biomarker rather than a dynamic therapeutic target in mid-to-late adulthood.

  17. The spectrum of Alzheimer's disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv : the preprint server for health sciences 2025-11-19 Tau biomarkers

    While hippocampal (H) and inferior parietal lobule (IPL) atrophy are used routinely in Alzheimer's disease (AD) diagnostics, the role of enlarged choroid plexus (ChP) remains unclear.

  18. Automated Plasma Phospho-tau217 Assays for the diagnosis of Down Syndrome-Related Alzheimer's Disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2025-09-01 Down syndrome and Alzheimer's

    Individuals with Down syndrome (DS) develop a genetic form of Alzheimer’s disease (AD) due to an extra copy of chromosome 21, which contains the APP gene.

  19. Epigenetic clocks and longitudinal plasma biomarkers of Alzheimer's disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv : the preprint server for health sciences 2025-08-14 Biomarkers

    At baseline, higher AgeAccelPheno was associated with lower amyloid-β42 to amyloid-β40 (Aβ42:Aβ40) ratio, and higher AgeAccelGrim2 was associated with elevated neurofilament light (NfL).

  20. Misfolded alpha synuclein co-occurrence with Alzheimer's disease proteinopathy

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv : the preprint server for health sciences 2024-10-13 Brain tissue and pathology

    Syn positivity (synSAA+) co-occurred with T (in synSAA+ vs synSAA-, 36% vs 20% T+; p=0.011) and with cognitive impairment (10% vs 7% MCI; 10% vs 0% dementia; p=0.00050). synSAA+ participants' cognitive performance declined ∼40% faster than synSAA-for Digit Symbol, but not other tests.

  21. Cortical Tau Aggregation Patterns associated with Apraxia in Alzheimer's Disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv : the preprint server for health sciences 2024-04-10 Brain scans and imaging

    We identified significant clusters of tau-aggregation in praxis-related regions (e.g., supramarginal gyrus, angular gyrus, temporal, parietal and occipital regions) that were associated with apraxia.

  22. A limbic-predominant amnestic neurodegenerative syndrome associated with TDP-43 pathology

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv : the preprint server for health sciences 2023-11-20 Brain tissue and pathology

    When seen in isolation, LATE-NC have been associated with a predominantly amnestic profile and slow clinical progression.

  23. Novel CSF tau biomarkers can be used for disease staging of sporadic Alzheimer's disease

    ⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. medRxiv : the preprint server for health sciences 2023-07-16 Tau biomarkers

    Biological staging of individuals with Alzheimer's disease (AD) may improve diagnostic and prognostic work-up of dementia in clinical practice and the design of clinical trials.

From across this topic

10 of the 1,573 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.

Other topics